INC Research Rated "Top CRO" by Investigative Sites Globally

Raleigh, N.C., May 1, 2013 - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, is ranked the "Top CRO" in the 2013 CenterWatch Global Investigative Site Relationship Survey. Results of the survey were published earlier today by CenterWatch, with INC Research receiving the highest "excellent" scores in six out of seven working relationship categories among all CROs included in the survey, a reflection of the Company's continued focus on developing strategic relationships with sites.  

"Quality relationships with investigative sites around the world are a critical success factor in delivering clinical trial results on time and on budget for our customers," said Jamie Macdonald, Chief Executive Officer. "This recognition is a testament to the value we provide to our partners through our people and our approach to clinical development. We are pleased that investigative sites worldwide have validated our focus on building long-lasting relationships."

INC Research was rated a top-three CRO in all 36 individual project attributes across the seven relationship categories included in the survey. The Company received some of its highest scores in maintaining a professional staff - monitors, medical experts and administrative support - and for being well organized and prepared in supporting studies. The 2013 survey also asked sites to evaluate CROs for the first time on their overall reputation in the industry, with INC being one of only four global CROs to rank in the top five in both reputation and direct working relationship quality.

CenterWatch conducted the biannual global survey of investigative sites during November/December 2012 and January 2013, soliciting online responses from principal investigators, sub-investigators and study coordinators about the quality and effectiveness of their relationships with the CROs they have worked with in the past two years. A total of 2,032 sites worldwide completed the survey - the highest response rate ever achieved for this survey - which evaluated the performance of CROs across 36 specific relationship attributes. Rankings are based on a combination of two measures: an overall relationship quality rating based on "excellent" scores from sites, and the frequency with which companies placed among the top-three rated CROs across the 36 relationship attributes measured.

INC Research's rating as the top CRO to work with is a direct reflection of the Company's dedication to providing optimal service to the investigators engaged in its studies. The Company has dedicated global departments focused specifically on enhancing site relationships and works with sites in a collaborative partnership to 
improve cycle times and standardize start-up activities to drive efficiency.

About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visitwww.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1 (513) 345-1685

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.